Apricus Biosciences (APRI) Shares Gap Up to $2.70
Apricus Biosciences Inc (NASDAQ:APRI) gapped up before the market opened on Tuesday . The stock had previously closed at $2.90, but opened at $2.70. Apricus Biosciences shares last traded at $2.70, with a volume of 3826800 shares traded.
Several equities research analysts have issued reports on APRI shares. Zacks Investment Research upgraded shares of Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Tuesday, October 31st. HC Wainwright reiterated a “buy” rating and set a $4.50 price objective on shares of Apricus Biosciences in a research note on Friday, November 3rd. Finally, ValuEngine upgraded shares of Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
An institutional investor recently bought a new position in Apricus Biosciences stock. Healthcare Value Capital LLC bought a new position in shares of Apricus Biosciences Inc (NASDAQ:APRI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences makes up approximately 0.6% of Healthcare Value Capital LLC’s investment portfolio, making the stock its 8th largest holding. Healthcare Value Capital LLC owned about 0.66% of Apricus Biosciences as of its most recent SEC filing. Institutional investors own 24.01% of the company’s stock.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.